Quick Takeaways: Why It Matters? Boehringer Ingelheim’s quarterable Previcox tablets strengthen its differentiation in canine pain management by enabling more precise weight-based dosing and improved flexibility. The sustainability-focused redesign may further enhance bran...
Quick Takeaways: Why It Matters? CannEpil’s MUMS designation could give Endovia and Lupvindol an early-mover advantage in veterinary oncology pain management, particularly if the conditional pathway enables faster commercialization. A potential 2027 launch may expand cannabinoi...
Quick Takeaways: Why It Matters? PetVivo’s new study shows that a single intra-articular Spryng injection with OsteoCushion technology can improve pain and function in dogs with stifle osteoarthritis and suspected cranial cruciate disease. While the authors call for larger studies with obj...
Quick Takeaways: Why It Matters? Akston could emerge as a serious competitor in the fast-growing anti‑NGF OA segment that Zoetis currently leads with its once‑monthly monoclonal. Because Akston’s Ambifect approach stimulates sustained endogenous anti‑NGF antibody responses, AKS‑548d remain...
